LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting
Eight scientific posters demonstrate significant seizure reduction and improved outcomes with VNS Therapy in patients with Drug-Resistant Epilepsy
“At the heart of LivaNova’s purpose as a Company, we aim to help patients reclaim their lives by improving global access to epilepsy treatment and supporting better outcomes,” said
The scientific poster presentations feature new research from leading independent investigators in collaboration with scientific experts from
Abstracts and posters will be available on the AES website during and following the congress.
“We value the opportunity to share current evidence and deepen the understanding of VNS Therapy," said
- VNS Therapy is Associated with Reduced Severe Seizure Burden in Children Early in the Treatment (3 months) of DRE with Continued Improvement Over 36 Months (Poster 1.303) – Description: Children and adolescents showed early improvements at 3 months and sustained seizure frequency reductions through 36 months.
- CORE-VNS Study Full Cohort at 36 Months Demonstrates Significant Reduction in Severe Disabling Seizures (Poster 1.322) – Description: Median reductions of up to 95% in the most disabling seizure types, including focal impaired awareness and bilateral tonic-clonic seizures.
- CORE-VNS: VNS Therapy Demonstrates Consistent Safety and Effectiveness in People With and Without a History of Brain Surgery for Epilepsy (Poster 2.271) – Description: Similar safety and effectiveness profiles regardless of prior neurosurgical epilepsy intervention.
- Healthcare Resource Use in People with Drug-Resistant Epilepsy Prior to Neuromodulation: Comparison of Commercially Insured, Medicare, and Medicaid Cohorts (Poster 2.101) – Description: High pre-implantation healthcare utilization and costs highlight unmet needs across private insurance, Medicare, and Medicaid recipients.
-
Healthcare Services and Costs 2-years Pre- and Post-VNS Therapy Implantation Across
U.S. Payer Types (Commercial, Medicare, and Medicaid) (Poster 2.088) – Description: VNS Therapy was associated with reductions in hospitalizations, emergency department visits, and overall costs post-implantation compared to projected continued use of traditional anti-seizure medications (ASMs).
- Use of VNS Therapy After Two Failed Anti-Seizure Medications is Associated with Significantly Greater Clinical Outcomes in People with Drug-Resistant Epilepsy (Poster 3.480) – Description: Patients treated earlier (after 2-3 ASMs) achieved a 94% median reduction in seizure frequency at 36 months versus 57% for those treated after >10 ASMs.
- Does Time Since Epilepsy Diagnosis Matter When Adding VNS Therapy for DRE? (Poster 3.479) – Description: Earlier implantation was related to greater seizure reduction (up to 88%), though number of prior medication failures was a stronger predictor of seizure frequency reduction.
-
VNS Therapy is Associated with a Significant Decrease in
Rescue Medication Administration in People with Drug-Resistant Epilepsy (Poster 3.478) – Description: Patients reported significant decreases in rescue medication use at the first study visit with a >70% decrease at 36 months.
About CORE-VNS
CORE-VNS is a real-world, long-term, open-label study focused on the outcomes of VNS Therapy in people diagnosed with DRE. Having enrolled more than 800 people from 61 worldwide sites, the study is the most comprehensive assessment of the effectiveness of VNS Therapy to date and provides modern insights into the global use of VNS Therapy in the management and control of seizures.
Adverse events in the CORE-VNS study were typical of those reported in the product labeling and experienced following placement of a VNS Therapy device. The most commonly reported (>5%) adverse events overall included respiratory, thoracic, and mediastinal disorders (dysphonia, dyspnea, cough) and general disorders/administration site conditions. See important safety information at VNSTherapy.com/safety.
About VNS Therapy for Epilepsy
VNS Therapy™ is clinically proven safe and effective as an add-on treatment to reduce the frequency of seizures in adults and children as young as 4 years old with DRE and partial onset seizures. It is a unique treatment approach developed for people with DRE—a condition that affects approximately one in three people with epilepsy. Unlike some other surgical treatment options for people with DRE, VNS Therapy implantation involves an outpatient procedure and does not require penetration of the skull. Outside
About
Safe Harbor Statement
This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding upcoming events, clinical research, and the treatment of Drug-Resistant Epilepsy with VNS Therapy. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251203929955/en/
LivaNova Investor Relations and Media Contacts
+1 281-895-2382
VP, Investor Relations
InvestorRelations@livanova.com
VP, Corporate Communications
Corporate.Communications@livanova.com
Source:
